novo nordisk cuts prices for its glp-1 drugs. The weight loss drug race is now a battle of pricing, access & market share. , has announced a cut in US of Wegovy and Ozempic amid competition from Eli Lilly’s Mounjaro. Novo Nordisk cuts Wegovy and
Description
A study found that while the drug is effective in weight management throughout therapy, discontinuing use will result in the patient regaining weight
This conservative stance protects patients from potential harm while research continues
Although lixisenatide is administered once a day, it is still considered a short-acting GLP-1RA [18]
While GLP-1 therapies improve endothelial function and reduce inflammation, they may also influence heart rate
